



King County Medical Society
COMMUNITY FOUNDATION

PD-L1 TESTING & IMMUNOTHERAPY

Immunotherapy is transforming treatment for recurrent and metastatic cervical cancer.

PD-L1 testing identifies patients most likely to benefit from checkpoint inhibitors such as pembrolizumab.



- ✓ **When to Test:** Conduct PD-L1 CPS scoring (>1) at recurrence or metastatic diagnosis.
- ✓ **Therapies to Know:** Pembrolizumab, atezolizumab, and combination regimens.
- ✓ **Implementation Tips:** Add PD-L1 to EHR order sets; confirm path lab reporting format.
- ✓ **Fast Action:** Use KCMS quick guide for CPS calculation and documentation standards.

MORE INFORMATION

- 🌐 NCCN Guidelines, Cervical Cancer, 2025
- 🌐 kcmsociety.org

For resources and downloadable templates: kcmsociety.org

Developed by the KCMS Community Foundation with grant support from Pfizer and Genmab.